

CUMULATIVE INDEX 2000

Volume 27

March	NUTRITION AND METABOLISM OF THE MICROPREMIE, pages 1-254
June	OUTCOME OF THE VERY LOW-BIRTH WEIGHT INFANT, pages 255-505
September	NEONATAL HEMATOLOGY, pages 507-760
December	CONGENITAL ANOMALIES, pages 761-1046

Note: Page numbers of issue titles and article titles are in **boldface** type.

- Abdominal wall anomalies, 917-919,
947-978
alpha-fetoprotein levels in, 948
Beckwith-Wiedemann syndrome, 965
bladder exstrophy, 925-926, 952, 962-963
body stalk anomaly, 949, 952-954
cloacal exstrophy, 925-926, 952, 960-962
embryology of, 947-948, 950-951
gastroschisis, 918-919, 954-958
genetic testing in, 949
omphalocele, 917-918, 952, 963-965
in cloacal exstrophy, 952, 961-962
in trisomies, 764
pentalogy of Cantrell, 952, 958-960
ultrasonography of, 948-949
umbilical cord, 965-972
- Abdominoschisis, 918-919, 954-958
- Abruption, placental, as cerebral palsy
antecedent, 290
- Acardia (twin reversed arterial perfusion
syndrome), 1038-1042
- Achondrogenesis, 988-990
- Achondroplasia, heterozygous, 983-984
homozygous, 987
- Acidosis, metabolic, as cerebral palsy
antecedent, 294
- Adolescents, as very low-birth weight
infant survivors, early pain
experience and, 371-372
growth of, 421-428
height, 425-428
weight, 422-425, 427-428
quality of life perceptions of, 407-416
respiratory health of, 428-431
- Age, maternal, in outcome of very
low-birth weight infants, 443-444,
446, 449-450
multiple gestation rate in, 347-350
versus energy expenditure, 185-186
- Agranulocytosis, infantile genetic, bone
marrow failure in, 553
- Akinesia deformation sequence, 998
- Alloimmunization, hydrops fetalis in,
1016-1017, 1023
- Alpha-fetoprotein, abdominal wall defects
and, 948
- Alport's syndrome, thrombocytopenia in,
663
- Amegakaryocytic thrombocytopenia, 662
bone marrow failure in, 547, 553
- Amino acids, parenteral, 198-207
administration strategies for, 206-207
drug effects on, 206
early introduction of, 200-201
energy intake and, 202-205
for protein accretion, 45
illness effects on, 205
quality of, 199-200
quantity of, 198-199
stress and, 205-206
toxicity of, 200, 202
- Amnioreduction, in twin-twin transfusion
syndrome, 1024
- Amniotic fluid, analysis of, in preterm
birth prediction, 272-273
fetal renal function and, 922-923
granulocyte colony-stimulating factor in,
561-562

- Amniotic fluid (*Continued*)
 infection of, as cerebral palsy antecedent, 289-290
 hydrops fetalis in, 1014-1016, 1022-1023
 septostomy for, in twin-twin transfusion syndrome, 1024, 1036-1037
 serial reduction of, in twin-twin transfusion, 1036
- Anabolism, eosinophilia in, 617
- Analgesia, for very low-birth weight infants, 374
- Anemia, aplastic, congenital syndromes with, 548-552
 Diamond-Blackfan, bone marrow failure in, 547, 552-553
 erythrocyte transfusions in, 734-735
 erythropoietin in, 741-743
 Fanconi's, bone marrow failure in, 546, 548-550
 thrombocytopenia in, 662
 hemolytic, in Rh mismatch, erythropoietin in, 690
 immune globulin in, 737-739
 hydrops fetalis in, 1016-1017, 1023
 iron-deficiency, in micropremies, 119-121
 physiologic, erythropoietin replacement in, 683-687
 physiology of, 682-683
- Anencephaly, 792
- Anesthesia, for very low-birth weight infants, 364-365, 374
- Aneuploidy, echogenic bowel in, 774-775, 913
- Aneurysm, of umbilical cord, 969
- Angiogenesis, erythropoietin in, 530-531
- Angiography, in thrombosis, 628
- Antibiotics, eosinophilia due to, 617-618
 in neutropenia, 585-586
 in preterm labor prevention, 276
- Antioxidants, bilirubin as, 174-175
 in lipid emulsions, 84
 vitamin C as, 96-97
- Antithrombin deficiency, thrombosis in, 627, 629-631
- Anus, disorders of, 912
- Aorta, coarctation of, 845-847
 thermocoagulation of, in twin reversed arterial perfusion syndrome, 1042
 thrombosis in, 627
 ventral aspect of, erythropoiesis in, 509-510
- Apert's syndrome, 820
- Apgar score, as cerebral palsy predictor, 292
- Aplastic anemia, congenital syndromes with, 548-552
- Appropriate-for-gestational age, 326
- Arachidonic acid metabolites, in labor control, 266-267
- Arachnoid cysts, 809
- Arousal, in preterm infants, early pain experience and, 373
- Arrhythmias, cardiac, hydrops fetalis in, 1013, 1020-1022
- Arteriovenous malformations, of central nervous system, 804
 of umbilical cord, 969
- Arthrogryposis, 998-1000
- Ascites, in hydrops fetalis, 1008-1010
- Ascorbic acid (vitamin C), metabolism and requirements of, in micropremies, 96-97
- Asphyxia, as cerebral palsy antecedent, 292
 fluid and electrolyte disorders in, in micropremies, 132
 thrombocytopenia in, 666
- Asphyxiating thoracic dystrophy, 991
- Assisted reproductive technology, economic issues in, 491
 multiple gestations in, outcome of, 347-350, 356-357
- Ataxia-pancytopenia syndrome, bone marrow failure in, 547
- Atelosteogenesis, 996
- Atrial measurement, in ventriculomegaly, 797-799
- Atrioventricular septal defect, 840-843
- Attention, in preterm infants, early pain experience and, 373
- Autonomic function, in very low-birth weight infants, pain effects on, 365
- Bacterial vaginosis, preterm birth in, 270
- Bacteroides* infections, preterm birth in, 269
- Ballantyne syndrome, 879
- Banana sign, of spina bifida, 793-795
- Barth syndrome, bone marrow failure in, 547
- Battelle Developmental Inventory, in very low-birth weight infant evaluation, 391
- Beckwith-Wiedemann syndrome, 965
- Behavioral development, in very low-birth weight infant survivors, family and social factors affecting, 444-445
 pain experience effects on, 371-372
- Biliary disorders, 915
- Bilirubin, as antioxidant, 174-175
 excess of. See *Hyperbilirubinemia*.
 metabolism of, lipid emulsions and, 62-63
 physiology of, in micropremies, 173-174
- Biology, in outcome of extremely low-birth weight infants. See *Extremely low-birth weight infants, outcome of, biology versus environment*.

- Biopsy, bone marrow, approach to, 750-751
 in neutropenia, 584-585
 in thrombocytopenia, 669
- Biotin, metabolism and requirements of, in micropremies, 103-104
- Birth weight, as survival predictor, 255-256
 extremely low. See *Extremely low-birth weight infants*.
 in multiple gestations, 351-352
 discordance in, 352-353
 versus development, 437-439, 444
 versus gender, 326-327
 versus gestational age, 326-327
 versus limitations, 446
 versus medical costs, 485-489
 very low. See *Very low-birth weight infants*.
- Bladder, anomalies of, in cloacal exstrophy, 925-926, 952, 960-962
 exstrophy of, 925-926, 952, 962-963
 obstruction of, 930-933
- Bleeding, vaginal, as cerebral palsy antecedent, 290
- Bleeding time test, 643-654
 abnormalities of, causes of, 649-651
 gestational age and, 651
 hemostasis physiology and, 644-646
 historical background of, 643-644
 interpretation of, 647-651
 procedure for, 646-647
 reference value for, 647
- Blood pressure, in very low-birth weight infants, pain effects on, 365
- Body stalk anomaly, 949, 952-954
- Bone, anomalies of. See *Skeletal anomalies*.
- Bone marrow, biopsy of, approach to, 750-751
 in neutropenia, 584-585
 in thrombocytopenia, 669
- erythropoiesis in, 510-511
- failure of, 543-558
 approach to, 545, 548
 congenital conditions associated with, 543-547
 differential diagnosis of, 548
 in amegakaryocytic thrombocytopenia, 547, 553
 in ataxia-pancytopenia syndrome, 547
 in Barth syndrome, 547
 in Diamond-Blackfan anemia, 547, 552-553
 in Down syndrome, 546, 551-552
 in Dubowitz syndrome, 546
 in dyskeratosis congenita, 550-551
 in Fanconi's anemia, 546, 548-550
 in infantile genetic agranulocytosis (Kostmann's syndrome), 553
 in IVIC syndrome, 547
 in Pearson's syndrome, 547
 in Seckel's syndrome, 546
 in Shwachman-Diamond syndrome, 546, 550
 in thrombocytopenia-absent radius syndrome, 547, 554-555
 in WT syndrome, 547
- Bone mineral metabolism, in micropremies, 147-170
 after discharge, 162-164
 before discharge, 157-162
 fetal development and, 148-153
 in first weeks, 157
 nutrition and, 153-157
 with human milk feeding, 242-243
- Bowel. See also *Small intestine*.
 echogenic, in ultrasonography, 774-775, 912-914
- Brain, arteriovenous malformations of, 804
 choroid plexus cysts of, 778-780, 802-803
 corpus callosum agenesis in, 799-800
 development of, 303-323
 essential fatty acids for, 85-86
 imaging of, functional, 318-319
 in intraventricular hemorrhage, 311
 in periventricular leukomalacia, 312-314
 in ventricular enlargement, 314-315
 magnetic resonance. See *Magnetic resonance imaging, of brain*.
 predictive value of, 311-316
 strategies for, 305-309
 structural, 316-318
 timing of, 309-310
 ultrasonographic. See *Ultrasonography, cranial*.
 injury during, 304-305
 pain experience effects on, 371-372
 vitamin B₆ in, 101
- erythropoietin in, 533-535
 glucose requirements of, 11-12
 hemorrhage of. See also *Intraventricular hemorrhage*.
 essential fatty acid effects on, 83
 holoprosencephaly of, 800-802
 hydranencephaly of, 805-806
 hypoglycemia effects on, 11-12
 hypoxia of, essential fatty acid effects on, 83
 inadequate perfusion of, as cerebral palsy antecedent, 294
 neural tube defects of, 791-795
 porencephaly of, 806
 posterior fossa anomalies of, 806-809
 schizencephaly of, 806
 tumors of, 804
 ventriculomegaly of. See *Ventriculomegaly*.
 white matter damage of. See *Cerebral palsy, antecedents of; Periventricular leukomalacia*.

- Braxton-Hicks contractions, 265
 Breast milk. *See Milk, human.*
 Bronchoalveolar lavage fluid, granulocyte colony-stimulating factor in, 562
 Bronchopulmonary dysplasia, anemia in, erythropoietin in, 687, 689
 eosinophilia in, 618
 essential fatty acid effects on, 81-82
 fluid and electrolyte disorders in, in micropremies, 141-142
 impact of, in adolescence, 428-431
 Bronchopulmonary sequestration, 881-886
 Burst-forming unit-erythroid cells, 512-513
- Calcification, papillary muscle, 776-778
 Calcium, homeostasis of, in fetus, 149-150
 in micropremies, 153-157
 vitamin D in, 106-108
 in enteral feeding, 155-157
 in parenteral nutrition, 154
 Calorimetry, in energy expenditure measurement, 183-184
 Campomelic dysplasia, 990-991
 Candidiasis, congenital, eosinophilia in, 614-615
 Cantrell-Haller-Ravitch syndrome (pentalogy of Cantrell), 952, 958-960
 Capillary leak syndrome, in micropremies, 134
 Carbohydrate:fat ratio, in parenteral nutrition, protein metabolism and, 30
 Carbon dioxide, measurement of, in indirect calorimetry, 183-184
 Cardiac arrhythmias, hydrops fetalis in, 1013, 1020-1022
 Cardiac output, disorders of, in micropremies, 133-134
 Cardiovascular system, disorders of, hydrops fetalis in, 1013, 1020-1022
 erythropoietin function in, 530-531
 Carnitine, in lipid emulsions, 60-61, 210-211
 Carotenoids, metabolism and requirements of, in micropremies, 104-106
 Cartilage anomalies. *See Skeletal anomalies.*
 Catheters, intravascular, dysfunction of, assessment of, 751
 thrombosis due to, 626-627
 CD34 molecule, of hematopoietic progenitor cells, 512-513
 Central nervous system. *See also Brain.*
 anomalies of, 791-812
 arteriovenous malformations, 804
 choroid plexus cysts, 778-780, 802-803
 corpus callosum agenesis, 799-800
 holoprosencephaly, 800-802
 hydranencephaly, 805-806
 intracranial tumors, 805
 neural tube defects, 791-795
 porencephaly, 806
 posterior fossa, 806-809
 schizencephaly, 806
 ventriculomegaly, 795-799
 erythropoietin in, 533-535
 Cephalocele, 792
 Cephalopagus, 1042-1043
 Cerebellum, malformations of, 807-809
 Cerebral palsy, 285-302
 antecedents of, asphyxia, 292
 cerebral perfusion abnormalities, 294
 delivery site effects on, 292-293
 detection of. *See Brain, development of, imaging of.*
 fetal growth restriction, 288
 genetic factors, 286-287
 hyperbilirubinemia, 294-295
 intrauterine infections, 289-290
 neonatal sepsis, 294
 placental abruption, 290
 preeclampsia, 288
 pregnancy factors, 287
 respiratory distress syndrome, 293
 thyroid hormone abnormalities, 287
 twin gestation, 287-288
 vaginal bleeding, 290
 definition of, 285
 functional assessment of. *See Functional outcome, of very low-birth weight infants, assessment of.*
 prevention of, antenatal magnesium sulfate in, 291-292
 antenatal steroids in, 291
 Cerebral ventriculomegaly. *See Ventriculomegaly.*
 Cerebrospinal fluid, erythropoietin in, 535
 Ceruloplasmin, deficiency of, 124-125
 Cervicothoracic somite dysplasia, 939
 Cervix, ripening of, in preterm labor, 273-275
 Cesarean section, in multiple gestations, 353
 Chemokines, reference ranges for, 604-608
 Chiari II malformations, 793-795
 Child care, in outcome of very low-birth weight infants, 445, 447
 Chlamydia infections, in chronic lung disease pathogenesis, 720
 preterm birth in, 268-270
 Chondrodysplasias. *See Skeletal anomalies.*
 Chondroectodermal dysplasia, 994-995
 Chorioamnionitis, as cerebral palsy antecedent, 289-290
 Choroid plexus cysts, 778-780, 802-803
 Chromosomal abnormalities, echogenic bowel in, 774-775, 913
 hydrops fetalis in, 1013-1014, 1022
 in abdominal wall anomalies, 949
 in umbilical cord anomalies, 949

- renal abnormalities in, 939-940
thrombocytopenia in, 662
ultrasonography in. *See* *Ultrasonography, in chromosomal abnormalities.*
- Chronic lung disease, cerebral palsy and, 293
 pathogenesis of, 717-731
 cytokines in, 719, 723-724
 granulocyte colony-stimulating factor in, 726-727
 granulocyte-macrophage colony-stimulating factor in, 724-726
 infections in, 720-721
 neutrophils in, 718-724
 oxyradicals in, 723
 proteases in, 721-723
 surfactant dysfunction in, 724
- Chylomicrons, artificial, in lipid emulsions, 58
- Chylothorax, fetal, 886-893
- Circumcision, pain response in, 369
- Cisterna magna enlargement, 806-807
- Cleft lip or palate, 823-829
- Cleft sternum, in pentalogy of Cantrell, 952, 958-960
- Cloacal exstrophy, 925-926, 952, 960-962
- Cloacal membrane, persistent, 931
- Coagulation, physiology of, 623-625
 vitamin K in, 111
- Coarctation, aortic, 845-847
- Cobalamin (vitamin B₁₂), metabolism and requirements of, in micropremies, 101-102
- Cognitive dysfunction, in intraventricular hemorrhage, 311
- Cognitive function, pain experience effects on, 371-372
- Colitis, necrotizing. *See* *Necrotizing enterocolitis.*
- Collagenase, in chronic lung disease pathogenesis, 722-723
- Colon, disorders of, 911-912
- Combined immunodeficiency syndrome, eosinophilia in, 616
- Communication skills, in very low-birth weight infant survivors, assessment of, 383-386, 395, 397
 family and social factors affecting, 444-445
- Competitive repopulating units, in erythropoiesis, 512
- Complement, in chronic lung disease pathogenesis, 718-719
- Congenital anomalies, abdominal wall, 947-978
 cardiac. *See* *Heart disease, congenital.*
 central nervous system, 791-812
 craniofacial, 813-837
 gastrointestinal, 901-920
 hydrops fetalis, 1007-1031
 in multiple gestations, 1033-1046
 neck, 813-837
 sonographic markers of, 761-789
 umbilical cord, 947-978
 urologic, 921-945
- Conjoined twins, 1042-1045
- Contractions, Braxton-Hicks, 265
- Contractures, joint, in arthrogryposis, 998-1000
- Copper, metabolism and requirements of, in micropremies, 123-125
- Cord blood, granulocyte colony-stimulating factor in, 560-561
- Corpus callosum, agenesis of, 799-800
- Corticogenesis, imaging of, 316-318
 injury effects on, 304-305
- Corticosteroids, antenatal, in cerebral palsy prevention, 291
 in thrombocytopenia, 670
- Corticotropin-releasing hormone, in labor control, 265-266
- Cortisol, in labor control, 265-266
- Cranial ultrasonography. *See* *Ultrasonography, cranial.*
- Cranioarachischis, 792
- Craniofacial anomalies, 813-837
 evaluation of, in skeletal anomalies, 982
 in achondrodysplasia, 983
 in achondrogenesis, 988-990
 in campomelic dysplasia, 990-991
 in holoprosencephaly, 801
 in thanatophoric dysplasia, 985
 syndromes associated with, 814-817, 820
- Craniopagus, 1042-1043
- Craniosynostoses, 820
- Crouzon's syndrome, 820
- Cylosomas (body stalk anomaly), 949, 952-954
- Cyst(s), adenomatoid, of lung, 875-881, 1023-1024
 arachnoid, 809
 choroid plexus, 778-780, 802-803
 kidney, 933-937
 mesenteric, 916
 omental, 916
 umbilical cord, 967-968
- Cystic adenomatoid malformation, of lung, 875-881, 1023-1024
- Cystic fibrosis, meconium ileus in, 913
- Cystic hygroma, 831-833
 in achondrogenesis, 988
 ultrasonography of, 763
- Cytidiltransferase, essential fatty acid interactions with, 79-80
- Cytokines, as preterm birth markers, 271-273
 hematopoietic, in necrotizing enterocolitis. *See* *Necrotizing enterocolitis.*
 in chronic lung disease pathogenesis, 723-724

- Cytokines (*Continued*)
 in labor control, 267
 Cytomegalovirus infections, hydrops
 fetalis in, 1015-1016
 Cytopenias. See also specific disorders.
 in bone marrow failure. See *Bone marrow, failure of*.
- Dandy-Walker syndrome and variants,
 807-809
 Death, due to lipid emulsions, for
 micropremies, 61-62
 fetal, cerebral palsy risk in surviving
 twin, 288
 in multiple gestations, 354-355
 in hydrops fetalis, 1010-1011
 neonatal, in multiple gestations, 355
 Delivery, preterm. See *Preterm labor and birth*.
- Dentinogenesis imperfecta, 994
 Deuterium-labeled water, in energy
 expenditure measurement, 184-185
 Diabetes mellitus, maternal, neonatal
 thrombosis in, 626
 Diamond-Blackfan anemia, bone marrow
 failure in, 547, 552-553
 Diaphragmatic hernia, 866-875
 antenatal history of, 869-870
 antenatal management of, 870-874
 epidemiology of, 866
 pathophysiology of, 866-867
 peritoneopericardial, 952, 958-960
 postnatal management of, 874-875
 prenatal diagnosis of, 867-869
 prognosis of, 870
 Diastrophic dysplasia, 995-996
 Digoxin, in twin-twin transfusion, 1036
 Diplegia, in cerebral palsy, functional
 motor outcome in, 385-387
 Direct calorimetry, in energy expenditure
 measurement, 184
 Disablement, models of, 382-383, 395
 Disseminated intravascular coagulation,
 thrombocytopenia in, 664
 Diuresis, in bronchopulmonary dysplasia,
 142
 in respiratory distress syndrome, 138,
 140
 Double-inlet ventricle, 858-859
 Double-outlet right ventricle, 854-856
 Doubly labeled water method, in energy
 expenditure measurement, 184-185
 Down syndrome. See *Trisomy 21 (Down syndrome)*.
- Drugs, bleeding time test interpretation
 and, 650
 eosinophilia due to, 617-618
 thrombocytopenia due to, 663-664
- Dual x-ray absorptiometry, in fetus,
 150-153
 in micropremies, 158-159, 161
 Dubowitz syndrome, bone marrow failure
 in, 546
 Duodenum, atresia of, 907
 disorders of, 908-910
 Dyskeratosis congenita, bone marrow
 failure in, 550-551
- Eagle-Barrett syndrome, 931
 Ear, anomalies of, 816, 829
 Ebstein's anomaly, 847-849
 Echocardiography, in thrombosis, 628-629
 Echogenic bowel, in ultrasonography,
 774-775, 912-914
 Economics, of prematurity, 483-497
 after neonatal period, 491-493
 cost reduction in, 493
 direct medical costs, 491-492
 nonmedical costs, 492
 in neonatal period, 485-491
 assisted reproductive technology
 effects on, 491
 cost-effectiveness, 490-491
 cost predictors in, 488-489
 cost reduction in, 489-491
 intensive care unit rationing in,
 489-490
 nonmedical costs, 488
 parental time, 488
 prenatal care effects on, 490
 regionalized care in, 490
 versus birth weight, 485-488
 methodologic issues in, 484-485
 terminology of, 484-485
- Edema, in micropremies, 132-135
 in asphyxia, 132
 in capillary leak syndrome, 134
 in immature organ development,
 132-134
 in sepsis syndrome, 132
 treatment of, 134-135
 pulmonary. See *Pulmonary edema*.
- Education, maternal, in outcome of very
 low-birth weight infants, 443-444,
 448-449
 multiple gestation rate in, 347-350
 special, prematurity-associated, 492-494
 Edwards' syndrome. See *Trisomy 18 (Edward's syndrome)*.
- Eicosanoids, synthesis of, essential fatty
 acids in, 80
 Elastase, in chronic lung disease
 pathogenesis, 722
 Electrolytes, metabolism of. See *Fluid and electrolyte metabolism*.
- Ellis-van Creveld syndrome, 994-995

- Emulsions, lipid. See *Lipids, emulsions of*.
- Encephalocoele, 792
- in Meckel-Gruber syndrome, 937-939
- Endothelial cells, erythropoietin function in, 530-531
- Endotoxin, as cerebral palsy antecedent, 289
- Energy, expenditure of, **181-195**
- factors affecting, 185-188
- in micropremies, 188-190
- versus requirements, estimation of, 189, 191-192
- in protein metabolism, 202-205
- measurement of, 183-185
- versus requirements, balance of, 181-183
- intake of, metabolizable, estimation of, 182
- requirements of, versus energy expenditure, balance of, 181-183
- versus expenditure, estimation of, 189, 191-192
- stores of, in neonate, 24-25
- Enteral feeding. See also *Milk, human*.
- in micropremies, **221-234**
- administration methods for, 227
- gut development and, 222-225
- long-term aspects of, 229
- milk selection for, 226-227
- minerals in, for bone growth, 155-157
- monitoring of, 229
- protein metabolism in, 28-29
- regime for, 225-226
- trophic feeding in, 227-229
- vitamin concentrations in, 98
- Enterocolitis, necrotizing. See *Necrotizing enterocolitis*.
- Enterocytes, erythropoietin in, 531-533
- Environment. See also *Family factors and social support*.
- in outcome of extremely low-birth weight infants. See *Extremely low-birth weight infants, outcome of, biology versus environment*.
- Eosinophil(s), adhesion of, 604-607
- formation of, 604
- life span of, 607
- migration of, 604-607
- physiology of, 603-607
- reference ranges for, 607-610
- Eosinophilia, **603-622**
- approach to, 618-619
- causes of, 610
- drug-induced, 617-618
- evaluation of, approach to, 746
- familial, 616-617
- in anabolic state, 617
- in bronchopulmonary dysplasia, 618
- in congenital heart disease, 618
- in congenital neutropenia with eosinophilia, 614
- in eosinophilic leukemia, 613-614
- in eosinophilic leukemoid reaction, 612-613
- in hypereosinophilic syndrome, 610-612
- in immunodeficiency, 616
- in infections, 614-615
- in thrombocytopenia-absent radius syndrome, 614
- physiology of, 603-607
- versus normal eosinophil concentrations, 607-610
- Eosinophilic leukemia, 613-614
- Eotaxin, reference ranges for, 605-608
- Epispadias, in bladder exstrophy, 952, 962-963
- Erythroblasts, in bone marrow, 510
- in liver, 510
- in yolk sac, 509
- primitive versus definitive, 508
- Erythrocyte(s), developmental disorders of, 552-553
- formation of. See *Erythropoiesis*.
- transfusions of, approach to, 734-735
- Erythropoiesis, **507-526**
- definition of, 507
- extramedullary, 511
- in aorta, 509-510
- in bone marrow, 510-511
- in liver, 510
- in yolk sac, 509
- switching from fetal to adult, erythrocyte characteristics, 514
- hemoglobin chain expression, 514-516
- precursors, 511-514
- primary site, 508-511
- primitive to definitive, 507-508
- regulation, 516-520
- Erythropoietin, abnormalities of, 527
- concentrations of, 517
- deficiency of, in physiologic anemia, 682-687
- developmental changes in, 516-520
- distribution of, 517
- gene of, regulation of, 519-520
- in transfusions, 527-529
- nonerythropoietic functions of, **527-541**
- in cardiovascular system, 530-531
- in central nervous system, 533-535
- in gastrointestinal system, 531-533
- overview of, 529-530
- production of, 517
- replacement of, **681-696**
- advantages of, 692-693
- approach to, 741-743
- in hyporegenerative anemias, 687-690
- in micropremies, 120-121
- in necrotizing enterocolitis, 700-703
- in physiologic anemia, 682-683
- clinical studies of, 683-687
- pharmacokinetics of, 690-691

- Erythropoietin (*Continued*)
 side effects of, 691
 transfusion requirements and, 683-688, 691-692
 structure of, 516
- Esophagus, atresia of, 903-905
 disorders of, 901-905
 embryology of, 901-903
 motility of, development of, 223
- Essential fatty acids. *See* *Fatty acids, essential.*
- Ethnic factors, in outcome of very low-birth weight infants, 440, 444, 446, 449-450
- Exchange transfusions, for hyperbilirubinemia, 176-178
- Exencephaly, 792
- Exomphalos (omphalocele), 917-918, 952, 963-965
 in cloacal exstrophy, 952, 961-962
 in trisomies, 764
- Exstrophy splanchnica (cloacal exstrophy), 925-926, 952, 960-962
- Exstrophy-epispadias complex (bladder exstrophy), 925-926, 952, 962-963
- Extracorporeal membrane oxygenation, in diaphragmatic hernia, 874-875
- Extremely low-birth weight infants, growth of, evaluation of, in adolescence, 421-428
 outcome of, biology versus environment and, 461-481
 articles reviewed, 463-464
 conceptual issues in, 476-478
 conclusions of, 470-473
 importance of, 462
 meaning of, 461-462
 mediation and moderation models, 471-472
 methodologic issues in, 476
 multiple risk models, 472-473
 protective factors in, 473-475
 studies reviewed, 463-470
 respiratory health in adolescence, 428-431
 survival rates, 255-262
- Eye, anomalies of, 814-815, 821-822
- Facial anomalies. *See* *Craniofacial anomalies.*
- Factor V Leiden mutation, thrombosis in, 629-631
- Family factors and social support. *See* also *Parents.*
 in outcome of very low-birth weight infants, 433-459
 data collection and management, 435-437
 research problem parameters, 433-435
 results, 437-452
 study goals, 435
- Fanconi's anemia, bone marrow failure in, 546, 548-550
- thrombocytopenia in, 662
- Fasting, protein metabolism in, in full-term neonates, 27
- Fatty acids, essential, 71-93
 brain injury and, 83
 deficit of, 84-86
 fetal stores of, 73-75
 in eicosanoid production, 80
 in formulas, 87
 in human milk, 86-87
 infections and, 82-83
 lipid membrane properties and, 78-79
 metabolism of, 71-73
 molecular biology of, 75-77
 oxidant stress from, 83-84
 pulmonary disease and, 81-82
 supplementation of, 84-87
 surfactant composition and, 79-80
 synthesis of, in marine environment, 87
 in lipid emulsions, 57-58
 peroxidation of, 64-65
- Feeding, of very low-birth weight infants. *See* *Growth, of very low-birth weight infants, in intensive care unit.*
- Fetal echogenic gut, 225
- Fetofetal transfusion syndrome. *See* *Twin-twin transfusion syndrome.*
- Fetus(es), bone development in, 148-153
 evaluation of, 150-153
 factors affecting, 148-150
 death of, cerebral palsy risk in surviving twin, 288
 in multiple gestations, 354-355
 essential fatty acid stores in, 73-75
 growth of, in multiple gestations, 351-352
 restriction of, cerebral palsy in, 288
 inflammatory response of, as cerebral palsy antecedent, 289-290
 multiple. *See* *Multiple gestations.*
 reduction of, in multiple gestations, 357-358
 vitamin D metabolism in, 106
- Fibrinolysis, physiology of, 623-625
- Fibronectin, fetal, as preterm birth marker, 271-272
- Fibrosis, pulmonary, in chronic lung disease, 721-724
- Filagragstim. *See* *Granulocyte colony-stimulating factor, therapeutic use of.*
- Fistula, tracheoesophageal, 903-905
- Fluid and electrolyte metabolism, in micropremies, 131-146
 disorders of, bronchopulmonary dysplasia, 141-142

- edema, 132-135
- hyperosmolar state, 135-138
- hyponatremia, 142-143
- pulmonary edema, 138-140
- respiratory distress syndrome. See *Respiratory distress syndrome.*
- shock, 132-135
- Folic acid, metabolism and requirements of, in micropremies, 102-103
- Formulas, for micropremies, 226-227
 - after discharge, 229
 - essential fatty acids in, 87
 - minerals in, for bone growth, 156-157, 159, 161, 163-164
 - vitamin concentrations in, 99
 - for very low-birth weight infants. See *Growth, of very low-birth weight infants, in intensive care unit.*
- Fracarro type of achondrogenesis, 988, 990
- Fractures, in congenital anomalies, 980
 - in hypophosphatasia, 987-988
 - in osteogenesis imperfecta, 992, 994
- Free radicals, in chronic lung disease pathogenesis, 723
- Functional Independence Measure for Children, in very low-birth weight infant evaluation, 390-394
- Functional outcome, of very low-birth weight infants, 381-401
 - assessment of, cohort studies of, 390-395
 - communicative skills, 383-386, 395, 397
 - developmental skills, 383-386
 - disability status, 395-396
 - disablement models for, 382-383
 - milestones in, 388-389
 - motor skills, 383-388
- Funic presentation, of umbilical cord, 970-971
- Gallbladder disorders, 915
- Gardnerella* infections, preterm birth in, 269
- Gastric emptying, in micropremies, 224
- Gastroesophageal reflux, in micropremies, 223
- Gastrointestinal tract, disorders of, 901-920
 - abdominal wall anomalies in. See *Abdominal wall anomalies.*
 - anorectal, 912
 - biliary, 915
 - colonic, 911-912
 - cysts, 916
 - duodenal, 908-910
 - echogenic bowel, 912-914
 - esophageal, 901-905
 - gallbladder, 915
 - gastric, 905-907
 - hepatic, 915
 - ileal, 910-911
 - jejunal, 910-911
 - pancreatic, 915-916
 - situs inversus, 916
 - small intestinal, 907-908
 - erythropoietin function in, 531-533
 - ontogeny of, 222-225
- Gastroschisis, 918-919, 954-958
- Gender, versus birth weight, 326-327
- Genes, essential fatty acid interactions with, 75-77
- Genetic factors, in cerebral palsy, 286-287
- Germinal matrix, hemorrhage into. See *Intraventricular hemorrhage.*
- Gestational age, as survival predictor, 255-259
 - bleeding time test and, 651
 - versus birth weight, 326-327
- Globin chains, of hemoglobin, switching from fetal to adult, 514-516
- Glucose, administration of, protein metabolism in, 29-30
 - requirements for, 207-208
 - homeostasis of, in micropremies, 1-22
 - evaluation of, 1-5
 - hyperglycemia and, 13-18
 - hypoglycemia and, 8-13
 - lipid emulsion effects on, 62
 - metabolism in, 1-2
 - normal levels in, 8-9
 - production of, 2-5
 - use of, 5-8
- Glucose transporters, in micropremies, 5-6, 15
- Glutamine, in protein accretion enhancement, 47-49
- Glutathione peroxidases, selenium in, 125-126
- Goiter, 834
- Gonorrhea, preterm birth in, 268
- Granulocyte(s), transfusions of, approach to, 737
- Granulocyte colony-stimulating factor, 559-576
 - actions of, 560-564
 - cells producing, 560
 - distribution of, 564-565
 - historical background of, 559
 - in amniotic fluid, 561-562
 - in bronchoalveolar lavage fluid, 562
 - in chronic lung disease pathogenesis, 726-727
 - in cord blood, 560-561
 - in fetal tissues, 564-565
 - in human milk, 562-564
 - in neonatal tissues, 564-565
 - in placenta, 564
 - in serum, 560-561
 - in urine, 562

- Granulocyte colony-stimulating factor
(Continued)
receptors for, distribution of, 564-565
functions of, 566-567
therapeutic use of, 567-570
 approach to, 739-741
 benefits of, 570
 in infections, 567-568
 in necrotizing enterocolitis, 701, 704
 in neutropenia, 588-590
 maternal, before delivery of extremely
 low-birth weight infants, 568-570
 pharmacokinetics of, 566-567
- Granulocyte-macrophage colony-
stimulating factor, in chronic lung
disease pathogenesis, 724-726
therapeutic use of, in labor control, 267
 in necrotizing enterocolitis, 701, 703-
 704
 in neutropenia, 590
- Gross Motor Functional Classification
System, disablement models of,
382-383
- Growth, catch-up, in very low-birth
weight infants, 339-343
 energy requirements for, 188
 estimation of, 191-192
 goals of, in parenteral nutrition, 211-214
 intrauterine, in multiple gestations, 351-
 352
 normal, 325-327
 restriction of, cerebral palsy in, 288
 in micropremies, 225
 thrombocytopenia in, 665
 ultrasonography of, 769
- of very low-birth weight infant sur-
 vivors, assessment of, in adolescence,
 421-428
- of very low-birth weight infants, in in-
 tensive care unit, 325-345
 clinical observations of, 328-333
 current perspective on, 339-341
 multicenter prospective cohort
 study of, 333-339
 research challenges on, 341-343
 versus normal fetal growth, 325-327
 with human milk feeding, in micropre-
 mies, 239-243
- Growth hormone, in protein accretion
enhancement, 47
- Head, anomalies of. See *Craniofacial
anomalies.*
- Health related quality of life. See *Quality of
life.*
- Health services and insurance, in outcome
of very low-birth weight infants, 441,
445, 447-450
- Hearing limitations, in very low-birth
weight infant survivors, family and
social factors affecting, 446-447
- Heart, absence of, in twins, 1038-1042
 immaturity of, fluid and electrolyte dis-
 orders in, in micropremies, 133-134
 papillary muscle calcification in, 776-778
 transplantation of, in hypoplastic left
 heart syndrome, 845
- Heart disease, congenital, 839-863
 aortic coarctation, 845-847
 atrioventricular septal defect, 840-843
 double-inlet ventricle, 858-859
 double-outlet right ventricle, 854-856
 Ebstein's anomaly, 847-849
 eosinophilia in, 618
 erythropoietin in, 690
 hydrops fetalis in, 1013, 1020-1022
 hypoplastic left heart syndrome,
 843-845
 hypoplastic right ventricle, 851
 tetralogy of Fallot, 851-854
 transposition of great arteries, 856-858
 truncus arteriosus, 859-861
 ventricular septal defect, 849-851
- Heart rate, in very low-birth weight
infants, pain effects on, 365
- Height, of very low-birth weight infant
survivors, in adolescence, 425-428
- Hemangioblasts, in yolk sac, 509
- Hematocrit, in erythrocyte transfusion
decisions, 734-735
- Hematology, bleeding time, 643-654
 bone marrow failure syndromes, 543-
 558
 chronic lung disease and, 717-731
 eosinophilia, 603-622, 746
 erythropoiesis, 507-526
 erythropoietin. See *Erythropoietin.*
 granulocyte colony-stimulating factor.
 See *Granulocyte colony-stimulating fac-
 tor.*
- hematopoietic growth factors, necrotiz-
 ing enterocolitis and, 697-716
 neutropenia. See *Neutropenia.*
- procedures and practices, 733-753
 bone marrow biopsy, 750-751
 catheter placement assessment, 751
 eosinophilia evaluation, 746
 erythropoietin administration, 741-743
 granulocyte colony-stimulating factor
 administration, 739-741
 immune globulin administration, 737-
 739
 neutropenia evaluation, 743-744
 neutrophilia evaluation, 744-746
 thrombosis evaluation, 747-750
 thrombosis treatment, 751-753
 transfusions, erythrocyte, 734-735
 granulocyte, 737
 platelet, 735-737
- thrombocytopenia. See *Thrombocytopenia.*
- thrombosis. See *Thrombosis.*

- Hematopoietic growth factors, in
erythropoiesis, switching from fetal to
adult, 513-514
- Hemicardia, in twins, 1039
- Hemiplegia, in cerebral palsy, functional
motor outcome in, 385-387
- Hemoglobin, switching from fetal to adult,
514-516
- Hemolytic disease, in Rh mismatch,
erythropoietin in, 690
hydrops fetalis in, 1017, 1023
immune globulin in, 737-739
- Hemorrhage. See also *Intraventricular
hemorrhage*.
brain, essential fatty acid effects on, 83
Hemostasis, physiology of, 644-646
- Heparin, in thrombosis, 631-632, 752-753
thrombocytopenia due to, 663-664
- Hepatic nuclear factor-4 α , in fatty acid
metabolism, 76-77
- Hernia, diaphragmatic, 866-875
peritoneopericardial, 952, 958-960
- Hitchhiker thumb, in diastrophic
dysplasia, 995
- Holoprosencephaly, 800-802
- HOX* gene, mutations of, multiple
anomalies in, 545
- Human milk. See *Milk, human*.
- Hyaline membrane disease, essential fatty
acid effects on, 81
- Hydranencephaly, 805-806
- Hydrocephalus, in ventriculomegaly,
795-799
- Hydronephrosis, 21, 775-776, 927-929
- Hydrops fetalis, **1007-1031**
counseling on, 1025-1027
definition of, 1007-1010
etiology of, 1012-1013
idiopathic, 1019
immune, 1012
in achondrogenesis, 988
in anemia, 1016-1017, 1023
in bronchopulmonary sequestration,
884-885
in cardiovascular disorders, 1013, 1020-
1022
in chromosomal abnormalities, 1013-
1014, 1022
in cystic adenomatoid malformation,
878-879, 1023-1024
in genitourinary malformations, 1018,
1024
in infections, 1014-1016, 1022-1023
in thoracic lesions, 1017-1018, 1023-1024
in tumors, 1018, 1024
in twin-twin transfusion syndrome,
1018-1019, 1024-1025
maternal complications in, 1025
morbidity in, 1011
mortality in, 1010-1011
prognosis for, 1019-1025
significance of, 1010-1011
syndromes associated with, 1014
ultrasonography of, 763
- Hydrothorax, 886-893
in hydrops fetalis, 1008-1010, 1023-1024
- 15-Hydroxyprostaglandin dehydrogenase,
in labor control, 266-267
- Hyperbilirubinemia, as cerebral palsy
antecedent, 294-295
in micropremies, **171-179**
benign neonatal, 174
developmental considerations in, 174-
175
diagnosis of, 175-176
outcome of, 178
pathophysiology of, 173-174
risks of, 174
treatment of, 171-173, 176-178
- Hyper eosinophilia, with
hyperimmunoglobulin E, 616
- Hyper eosinophilic syndrome, 610-612
- Hyperglycemia, in micropremies, 13-18
definition of, 13
glucose administration strategies and,
207-208
incidence of, 13-14
pathophysiology of, 15
treatment of, 16-18
- Hyperglycemic clamp technique, in
glucose metabolism evaluation, 3
- Hyperkalemia, nonoliguric, in
micropremies, 136-137
- Hyperosmolar state, in micropremies,
135-138
- Hypersensitivity, to pain, in preterm
infants, 367
- Hypertelorism, 814, 821-822
in arthrogryposis, 998
- Hypertension, maternal, neonatal
thrombocytopenia in, 665, 741
pulmonary, lipid emulsions and, 63-64
- Hyperventilation, as cerebral palsy
antecedent, 294
- Hypocalcemia, in micropremies, 154
of prematurity, 107
- Hypochondrogenesis, 990
- Hypoglycemia, in micropremies, 8-13
definition of, 8-10
incidence of, 10
pathophysiology of, 10-12
treatment of, 12-13
- Hyponatremia, of prematurity, 142-143
- Hypophosphatasia, skeletal anomalies in,
987-988
- Hypoplastic left heart syndrome, 843-845
- Hypoplastic right ventricle, 851
- Hypotelorism, 814, 822
- Hypothalamic-pituitary-adrenal axis, in
labor control, 265-266

- Hypothyroxinemia, cerebral palsy in, 287
- Hypoxemia, as cerebral palsy antecedent, 294
- Hypoxia, brain, essential fatty acid effects on, 83
- Hypoxia-inducible factor, in erythropoietin gene regulation, 519-520
- Ileum, disorders of, 910-911
- Imaging. *See Magnetic resonance imaging; Ultrasonography.*
- Immune globulin, intravenous, approach to, 737-739
- in neutropenia, 586-588
- in thrombocytopenia, 670
- Immunodeficiency, eosinophilia in, 616
- Immunoglobulin G, in platelets, in thrombocytopenia, 669
- Indirect calorimetry, in energy expenditure measurement, 183-184
- Indomethacin, in twin-twin transfusion, 1036
- thrombocytopenia due to, 663
- Infantile genetic agranulocytosis (Kostmann's syndrome), bone marrow failure in, 553
- Infections, eosinophilia in, 614-615
- essential fatty acid effects on, 82-83
- genital, as cerebral palsy antecedent, 289-290
- preterm birth in, 268-270
- granulocyte colony-stimulating factor in, 567-568
- immune globulin in, 737-739
- in chronic lung disease pathogenesis, 720-721
- intrauterine, hydrops fetalis in, 1014-1016, 1022-1023
- Infertility treatments, multiple gestations in, outcome of, 347-350, 356-357
- Inflammation, fetal response to, as cerebral palsy antecedent, 289-290
- genital, preterm birth in, 268-270
- Inflammatory mediators, in labor control, 267
- Iniencephaly, 793
- Insulin, in micropremies, in glucose metabolism, 4, 15
- in hyperglycemia, 17-18
- in protein accretion enhancement, 45, 47
- resistance to, 207-208
- Intake, dietary, energy expenditure related to, 186
- Intensive care unit, care rationing in, 489-490
- economics of. *See Economics, of prematurity.*
- growth in. *See Growth, of very low-birth weight infants, in intensive care unit.*
- Interleukin(s), as preterm birth markers, 271-273
- in chronic lung disease pathogenesis, 723
- in labor control, 267
- in necrotizing enterocolitis pathogenesis and treatment, 701, 704-710
- Interleukin-11, in thrombocytopenia, 670
- Intestine, necrotizing enterocolitis of. *See Necrotizing enterocolitis.*
- Intracranial pressure, in very low-birth weight infants, pain effects on, 365
- Intrauterine growth. *See Growth, intrauterine.*
- Intravenous therapy, for fluid and electrolyte disorders, in micropremies, in hyperosmolar state, 137-138
- in patent ductus arteriosus, 140
- in shock, 134-135
- nutritional. *See Parenteral nutrition.*
- Intraventricular hemorrhage, 304
- imaging of, for outcome prediction, 311
- types of, 315-316
- ultrasonography in, 305-307, 310
- Intrinsic factor, 101-102
- Intubation, for enteral feeding, in micropremies, 227
- Iodine, metabolism and requirements of, in micropremies, 126-127
- Iron, metabolism and requirements of, in micropremies, 119-121
- supplementation of, in erythropoietin therapy, 743
- Ischiopagus, 1044
- IVIC syndrome, bone marrow failure in, 547
- Jaundice, in micropremies, 171-179
- developmental considerations in, 174-175
- diagnosis of, 175-176
- lipid emulsion use in, 62-63
- outcome of, 178
- pathophysiology of, 173-174
- physiologic, 174
- risks of, 174
- treatment of, 171-173, 176-178
- Jejunum, disorders of, 910-911
- Jeune's syndrome (asphyxiating thoracic dystrophy), 991
- Joint contractures, in arthrogryposis, 998-1000
- Kernicterus, low-bilirubin, 172-173

- Kidney, agenesis of, 924-925, 939
 cystic, 933-937
 dysplasia of, in Meckel-Gruber syndrome, 937-939
 multicystic, 933-935
 embryology of, 921-922
 function of, in amniotic fluid formation, 922-923
 hydronephrosis of, 21, 775-776, 927-929
 imaging of, 923-924
 oxygen sensing in, in erythropoietin regulation, 520
 Kostmann's syndrome, bone marrow failure in, 553
- Labor and delivery, facilities for, versus cerebral palsy risk, 292-293
 preterm. *See Preterm labor and birth.*
 Langer-Saldino type of achondrogenesis, 990
 Language development, in very low-birth weight infant survivors, assessment of, 383-386, 395, 397
 family and social factors affecting, 444-445
 Large-for-gestational age, 326
 Lasers, in placental vessel ablation, for twin-twin transfusion, 1037-1038
 in umbilical cord coagulation, in twin reversed arterial perfusion syndrome, 1041-1042
 Lemon sign, of spina bifida, 793-795
 Leucine kinetics, in low-birth weight infants, 31, 33-36
 Leukemia, eosinophilic, 613-614
 in congenital bone marrow failure syndromes, 545
 Down syndrome, 551-552
 Fanconi's anemia, 549
 Shwachman-Diamond syndrome, 550
 Leukemoid reaction, eosinophilic, 612-613
 Leukotrienes, in labor control, 266-267
 Limb body wall complex, 949, 952-954
 Limbs, defects of, 996-997. *See also Skeletal anomalies.*
 measurement of, in anomaly detection, 980-981
 Limit of viability, in neonates, 259-260
 Lip, anomalies of, 823-829
 Lipid(s). *See also Fatty acids.*
 emulsions of, for micropremies, 57-69, 208-210
 antioxidants in, 84
 bronchopulmonary dysplasia and, 81-82
 carnitine supplementation in, 60-61, 210-211
 composition of, 57-58, 65
 essential fatty acids in, 84-86
 hyaline membrane disease and, 81
 infections and, 82-83
 infusion rate for, 59
 jaundice from, 62-63
 maximal intake, 209-210
 metabolism of, 58-61
 minimal intake, 208
 mortality and morbidity related to, 61-62
 peroxidation in, 64-65
 protein metabolism in, 30
 pulmonary function and pulmonary vascular resistance and, 63-64
 toxicity of, 209-210
 peroxidation of, essential fatty acids and, 83-84
 Lipid membranes, essential fatty acid effects on, 78-79
 Lipomyelomeningocele, 793-795
 Liver, disorders of, 915
 erythropoiesis in, 510
 oxygen sensing in, in erythropoietin regulation, 520
 Löffler's syndrome, eosinophilia in, 610-612
 Low-birth weight infants, extremely. *See Micropremies.*
 Lung, chronic disease of. *See Chronic lung disease.*
 cystic adenomatoid malformation of, 875-881, 1023-1024
 dysplasia of. *See Bronchopulmonary dysplasia.*
 edema of, in micropremies, 138-140
 embryology of, 866, 881
 immaturity of, fluid and electrolyte disorders in, in micropremies, 133-134
 lipid emulsion effects on, 63-64
 sequestration of, 881-886
 thoracic anomalies effects on. *See Thoracic anomalies.*
- McMaster studies, of quality of life, in very low-birth weight infants, 407-416
 Macrophage colony-stimulating factor, therapeutic use of, in necrotizing enterocolitis, 704
 Macrophage inflammatory proteins, reference ranges for, 605-608
 Magnesium sulfate, antenatal, in cerebral palsy prevention, 291
 Magnetic resonance imaging, of brain, functional, 317-318
 in periventricular leukomalacia, 312-314
 in ventriculomegaly, 315

- Magnetic resonance imaging (*Continued*)
 structural, 316-317
 versus ultrasonography, 315-316
 of cystic adenomatoid malformation, 876-878
- Managed care, in prematurity. See *Economics, of prematurity.*
- Mandible, anomalies of, 817, 829-831
- Manganese, metabolism and requirements of, in micropremies, 127
- Mean platelet volume, in thrombocytopenia, 667-668
- Meckel-Gruber syndrome, 937-939
- Meconium, obstruction from, 911-913
- Megacystis-microcolon-intestinal hypoperistalsis syndrome, 931-932
- Megakaryocyte(s), developmental disorders of, 553-555
- Megaureter, 930
- Megaurethra, 931-932
- Menaquinones (vitamin K), metabolism and requirements of, in micropremies, 110-112
- Meningocele, 792-795
- Menkes' syndrome, copper deprivation in, 124
- Mesenteric cysts, 916
- Metabolic acidosis, as cerebral palsy antecedent, 294
- Metabolic rate, resting, 182-183
- Metabolism, in micropremies. See *Micropremies, nutrition and metabolism in.*
- Metallothionein, synthesis of, zinc in, 122
- 3-Methylhistidine, measurement of, in protein metabolism studies, 26
- Microcephaly, 818
- Micrognathia, 817, 829-831
- Micropremies, nutrition and metabolism in, bilirubin, 63-64, 171-179
 bone mineral, 147-170
 electrolyte, 131-146
 energy, 181-195
 enteral, 221-234. See also *Milk, human, for micropremies.*
 essential fatty acid, 71-93
 glucose, 1-22
 human milk in, 235-247
 intravenous. See *Parenteral nutrition.*
 lipid, 57-69, 208-210
 protein. See *Amino acids; Protein metabolism.*
 trace element, 119-129
 vitamin, 95-118
 water, 131-146
- Milestones, in functional outcome assessment, 388-389
- Milk, human, for micropremies, 235-247
 after discharge, 239-243
 composition of, 235-236
 essential fatty acids in, 86-87
 fortifiers for, 226-227, 237-238
 health benefits of, 243-244
 minerals in, for bone growth, 156-157, 159, 161
 nutrient intake determination in, 237
 outcome data supporting, 238-239
 practical aspects of, 236-238
 versus formula, 226-227
 vitamin concentrations in, 99
 granulocyte colony-stimulating factor in, 562-564
- Mineralization, bone. See *Bone mineral metabolism.*
- Monocyte(s), granulocyte colony-stimulating factor production in, 560
- Morphine, for procedures, in very low-birth weight infants, 374
- Motility, of gastrointestinal tract, development of, 223-224
- Motor skills, in very low-birth weight infants, assessment of, 383-388
 family and social factors affecting, 444-445
- Movement, fetal, in skeletal anomalies, 982-983
- Multifetal pregnancy reduction, 357-358
- Multiple gestations, 347-361
 anomalies in, 1033-1046
 conjoined twins, 1042-1045
 twin reversed arterial perfusion syndrome, 1038-1042
 twin-twin transfusion syndrome, 1018-1019, 1024-1025, 1033-1038
 cerebral palsy risk in, 287-288
 iatrogenic, prevention of, 357-358
 maternal age and, 347-350
 maternal education and, 347-350
 outcomes of, 350-357
 assisted reproductive technology and, 347-350, 356-357
 delivery timing and, 353
 fetal growth, 351-352
 fetal mortality rates, 354-355
 growth discordance, 352-353
 very low-birth weight mortality and morbidities, 355-356
 zygosity and, 354
 prevention of, 357-358
 trends in, 347-350
- MURCS association, 939
- Mycoplasma* infections, in chronic lung disease pathogenesis, 720
 preterm birth in, 268-269
- Myelomeningocele, 793-795
- Myeloperoxidase, in chronic lung disease pathogenesis, 723
- Myofibrillary protein degradation, measurement of, 38-39

- Nasogastric tubes, for enteral feeding, 227
- National Center of Medical Rehabilitation Research, disablement models of, 382-383, 395
- Neck, anomalies of, 831-834
- Necrotizing enterocolitis, 697-716
- clinical features of, 698
 - course of, 698
 - essential fatty acid effects on, 82
 - etiology of, 698-700
 - hematopoietic growth factors and, 700-710
 - basic concepts of, 700-701
 - erythropoietin, 700-703
 - granulocyte colony-stimulating factor, 701, 704
 - granulocyte-macrophage colony-stimulating factor, 701, 703-704
 - interleukins, 701, 704-710
 - macrophage colony-stimulating factor, 701, 704
 - thrombopoietin, 701, 704
 - historical background of, 698
 - in enteral feeding, 227
 - in erythropoietin deficiency, 532-533
 - in intrauterine growth restriction, 225
 - incidence of, 698
 - significance of, 698
 - thrombocytopenia in, 665
- Neonatal Facial Coding System, in pain assessment, 366-367
- Neovascularization, erythropoietin in, 530-531
- Neural tube defects, 791-795
- Neuroimaging. *See Magnetic resonance imaging, of brain; Ultrasonography, cranial.*
- Neutropenia, 577-601
- alloimmune, 583-584
 - approach to, 577-578
 - autoimmune, 583-584
 - bone marrow aspiration in, 584-585
 - causes of, 579, 581-583
 - chronic idiopathic, 589
 - classification of, 579, 581-583
 - congenital, with eosinophilia, 614
 - definition of, 578
 - evaluation of, approach to, 743-744
 - granulocyte colony-stimulating factor in, 739-741
 - granulocyte transfusions in, 737
 - immune globulin in, 737-739
 - in erythropoietin replacement, 691
 - laboratory testing in, 583-584
 - treatment of, antibiotics in, 585-586
 - granulocyte colony-stimulating factor in, 588-590
 - intravenous immune globulin in, 586-588
 - neutrophil transfusion in, 590-591
 - versus normal neutrophil levels, 578-580
- Neutrophil(s), deficiency of. *See Neutropenia.*
- developmental disorders of, 553
- in chronic lung disease pathogenesis, 718-724
- consequences of, 721-724
 - control of, 724
 - cytokines in, 719, 723-724
 - infections and, 720-721
 - oxyradicals in, 723
 - proteases in, 721-723
 - stimuli for, 718-721
 - surfactant dysfunction in, 724
 - transfusions of, approach to, 737
 - in neutropenia, 590-591
- Neutrophilia, evaluation of, approach to, 744-746
- Niacin, metabolism and requirements of, in micropremies, 102
- Nitrogen balance, in low-birth weight infants, 30-32
- measurement of, 25-26
- Noonan's syndrome, thrombocytopenia in, 663
- Nose, anomalies of, 816, 823
- Nuchal cord, 971-972
- Nuchal thickening, ultrasonography of, 773-774
- Nuchal transparency, in ultrasonography, 764-769
- Nutrition, for very low-birth weight infants. *See Growth, of very low-birth weight infants, in intensive care unit.*
- in micropremies. *See Micropremies, nutrition and metabolism in.*
- Oligohydramnios, in Potter's syndrome, 923
- in twin-twin transfusion syndrome, 1018-1019, 1024-1025
- Omental cysts, 916
- Omphalocele, 917-918, 952, 963-965
- in cloacal exstrophy, 952, 961-962
 - in trisomies, 764, 917-918
- Ontogeny, of gastrointestinal tract, 222-225
- Orogastric tubes, for enteral feeding, 227
- Osteochondrodysplasias. *See Skeletal anomalies.*
- Osteogenesis imperfecta, 991-994
- Osteopenia, in micropremies, 157-158, 162
- Ovulation, induction of, multiple gestations in, 357
- Oxidation, of lipids, essential fatty acids and, 83-84
- Oxygen-18-labeled water, in energy expenditure measurement, 184-185
- Oxygen consumption, in indirect calorimetry, 183-184

- Oxyradicals, in chronic lung disease pathogenesis, 723
- Pain, in very low-birth weight infants, 363-379
 acute consequences of, 365
 anesthesia for, 364-365
 animal studies of, 372
 arousal regulation and, 373
 assessment of, 366-367
 attention regulation and, 373
 behavioral effects of, 371-372
 long-term sequelae of, 369-371
 management of, 374
 neurodevelopmental effects of, 371-372
 procedures causing, 363-365
 self-regulation and, 373
 short-term sequelae of, 367-369
- Palate, anomalies of, 823-829
- Pancreas, disorders of, 915-916
- Pancytopenias, in bone marrow failure.
See Bone marrow, failure of.
- Pantothenic acid, metabolism and requirements of, in micropremies, 103
- Papillary muscle calcification, 776-778
- Paraomphalocele (gastroschisis), 918-919, 954-958
- Parathyroid gland, function of, in fetus, 149-150
- Parenteral nutrition, for micropremies, 197-219
 amino acids in, 198-207
 calcium in, 154
 drug effects on, 206
 for protein accretion, 44-46
 glucose in, 29-30, 207-208
 growth outcome in, 211-214
 lipid emulsions for. *See Lipids, emulsions of.*
 phosphorus in, 154
 protein metabolism in, 29-30
 trophic feeding with, 227-228
 vitamin concentrations in, 99
 vitamin D in, 154-155
 in very low-birth weight infants, growth rates and, clinical observations of, 330-333
 prospective cohort study of, 333-339
 research challenges on, 342
- Parents, of very low-birth weight infants, quality of life perceptions of, 407-416
 time and medical costs of, 488
- Parvovirus B19 infections, hydrops fetalis in, 1015, 1022
- Patau's syndrome. *See Trisomy 13 (Patau's syndrome).*
- Patent ductus arteriosus, fluid and electrolyte disorders in, in micropremies, 140
- Pearson's syndrome, bone marrow failure in, 547
- Pediatric Evaluation of Disability Inventory, in very low-birth weight infant evaluation, 391
- Pena-Shokeir phenotype, of akinesia deformation sequence, 998
- Pentalogy of Cantrell, 952, 958-960
- Peritoneopericardial diaphragmatic hernia (pentalogy of Cantrell), 952, 958-960
- Peritonitis, meconium, 913
- Periventricular leukomalacia, 304-305
 antecedents of. *See Cerebral palsy, antecedents of.*
 imaging of, for outcome prediction, 312-314
 ultrasonography in, 305, 308, 310, 312
- Peroxidation, of fatty acids, in lipid emulsions, 64-65
 of lipids, essential fatty acids and, 83-84
- Peroxisome proliferator-activated receptor, in fatty acid metabolism, 76-77
- Pfeiffer's syndrome, 820
- Phenylalanine kinetics, in low-birth weight infants, 36-38
- Phospholipids, in lipid emulsions, 58-59
 synthesis of, essential fatty acids in, 80
- Phosphorus, in enteral feeding, 155-157
 in parenteral nutrition, 154
- Phototherapy, for hyperbilirubinemia, 176-178
- Phylloquinones (vitamin K), metabolism and requirements of, in micropremies, 110-112
- Physical activity, versus energy expenditure, 187
- Physical therapy, for low-birth weight infants, cost-effectiveness of, 493
- Pierre Robin syndrome, 830-831
- Placenta, abruptio of, as cerebral palsy antecedent, 290
 granulocyte colony-stimulating factor in, 564
 vessel ablation in, for twin-twin transfusion, 1037-1038
- Platelet(s), deficiency of. *See Thrombocytopenia.*
 function of, 644-646
 life span of, in thrombocytopenia, 668
 mean volume of, in thrombocytopenia, 667-668
 reference values for, 645
 reticulated, 668
 transfusions of, approach to, 735-737
 in thrombocytopenia, 669
- Pleural effusion, fetal, 886-893
- Pneumothorax, as cerebral palsy antecedent, 293

- Polycystic kidney disease, 933-937
- Polydactyly, 991
in chondroectodermal dysplasia, 994
in Meckel-Gruber syndrome, 937-939
- Polyhydramnios, in bronchopulmonary sequestration, 883
in diaphragmatic hernia, 868-870
in fetal hydrothorax, 886
in hydrops fetalis, 1009-1010
in skeletal anomalies, 982
in twin reversed arterial perfusion syndrome, 1038-1042
in twin-twin transfusion syndrome, 1018-1019, 1024-1025
- Polymerase chain reaction, for intrauterine infection diagnosis, 1016
- Polyunsaturated fatty acids. *See Fatty acids, essential.*
- Popliteal pterygium syndrome, 1000
- Porencephaly, 806
- Posterior fossa abnormalities, 806-809
- Potter's syndrome, 923
- Poverty, in outcome of very low-birth weight infants, 440, 443, 446, 449, 451
- Preeclampsia, cerebral palsy risk in, 288
- Prenatal care, in outcome of very low-birth weight infants, 444, 446, 448-450
- Preterm labor and birth, 263-283. *See also Very low-birth weight infants.*
definition of, 263
economics of. *See Economics, of prematurity.*
eosinophilia in. *See Eosinophilia.*
epidemiology of, 264
extremely low-birth weight. *See Micropremies.*
granulocyte colony-stimulating factor administration in, 568-569
in multiple gestations, 353
indicated, 264
markers of, amniotic fluid, 272-273
bacterial vaginosis, 270
cervical ripening, 273-275
clinical, 273-275
fetal fibronectin, 271-272
future research on, 275-276
genital infections and inflammation, 268-270
uterine activity, 275
mechanisms of, 264-267
endocrine control, 265-266
inflammatory mediators in, 267
prostaglandins in, 266-267
uterine activation, 264-265
necrotizing enterocolitis due to. *See Necrotizing enterocolitis.*
pathology of, 263-264
physiologic anemia in, 682-687
prevention of, in multiple gestations, 357-358
retinopathy in, erythropoietin in, 531
spontaneous, 264
Preterm milk. *See Milk, human, for micropremies.*
- Prostaglandin(s), in labor control, 266-267
synthesis of, essential fatty acids in, 80
in lipid emulsion administration, 62
- Prostaglandin-H synthase, in labor control, 266-267
- Proteases, in chronic lung disease pathogenesis, 721-723
- Protein C deficiency, thrombosis in, 627, 629-631
- Protein metabolism. *See also Amino acids.*
in micropremies, 23-56
energy expenditure in, 202-205
energy stores and, 24-25
factors affecting, 24
interventions for, 44-49
quantification of, 25-26
turnover in, 26-39
microfibrillar degradation in, 38-39
versus full-term infants, 27-30
versus low-birth weight infants, 30-35
versus very low-birth weight infants, 35-38
urea metabolism and, 40-44
- Protein S deficiency, thrombosis in, 627, 629-631
- Prune-belly syndrome, 931
- Pterygium syndromes, 998-1000
- Pulmonary edema, in micropremies, 138-140
- Pulmonary function, lipid emulsion effects on, 63-64
of very low-birth weight infant survivors, in adolescence, 428-431
- Pulmonary vascular resistance, lipid emulsion effects on, 63-64
- Pyloric hypertrophy, 907
- Pyophagus, 1044
- Pyridoxine (vitamin B₆), metabolism and requirements of, in micropremies, 101
- Quadruplegia, in cerebral palsy, functional motor outcome in, 385-387
- Quadruplet gestations. *See Multiple gestations.*
- Quality of life, of very low-birth weight infant survivors, 403-419
assessment of, 404-419
children, parent, and health professional comparisons in, 407-415
in care decision making, 415-416
preference measurements in, 405-406

Quality of life (*Continued*)

concept of, 403-404

Quintuplet gestations. *See Multiple gestations.*

Radioisotope studies, of energy expenditure, 184-185

of protein metabolism, 26
of urea metabolism, 40-43

RANTES, reference ranges for, 605-608

Rectum, disorders of, 912

Respiratory calorimetry, 183-184

Respiratory distress syndrome, as cerebral palsy antecedent, 293
essential fatty acid effects on, 81
fluid and electrolyte disorders in, 138-140

lipid emulsions and, 64

Respiratory health, of very low-birth weight infant survivors, family and social factors affecting, 446-447
in adolescence, 428-431

Respiratory quotient, 184

Respiratory syncytial virus infections, in low-birth weight infants, prevention of, 493

Resting metabolic rate, 182-183

Retinoids, metabolism and requirements of, in micropremies, 104-106

Retinopathy, of prematurity, erythropoietin in, 531

Rh antigen, mismatch of, hemolytic anemia in, erythropoietin in, 690
immune globulin in, 737-739

Rhabdomyosarcoma, cystic adenomatoid malformation associated with, 880-881

Riboflavin (vitamin B₂), metabolism and requirements of, in micropremies, 100-101Ribs, anomalies of, assessment of, 981
in asphyxiating thoracic dystrophy, 991

in hypophosphatasia, 987

in osteogenesis imperfecta, 992, 994

in short rib-polydactyly syndrome, 991

in thanatophoric dysplasia, 985-986

Rickets, in micropremies, 158

Risky maternal behavior, in outcome of very low-birth weight infants, 440, 445-446, 449, 451

Schizencephaly, 806

Sclerae, blue, in osteogenesis imperfecta, 992, 994

Seckel's syndrome, bone marrow failure in, 546

Selenium, metabolism and requirements of, in micropremies, 125-126

Self-regulation, in preterm infants, early pain experience and, 373

Sepsis, as cerebral palsy antecedent, 294
essential fatty acid effects on, 82-83
fluid and electrolyte disorders in, in micropremies, 132

granulocyte transfusions in, 737

immune globulin in, 737-739

neutropenia in, granulocyte colony-stimulating factor in, 739-741

Septostomy, amniotic, in twin-twin

transfusion syndrome, 1024, 1036-1037

Shock, granulocyte transfusions in, 737

immune globulin in, 737-739

in micropremies, 132-135

in asphyxia, 132

in capillary leak syndrome, 134

in immature organ development, 132-134

in sepsis syndrome, 132

treatment of, 134-135

Short rib-polydactyly syndrome, 991

Shwachman-Diamond syndrome, bone marrow failure in, 546, 550

Siamese twins, 1042-1045

Situs inversus totalis, 916

Skeletal anomalies, 979-1005

achondrogenesis, 988-990

achondroplasia, heterozygous, 983-984

homozygous, 987

arthrogryposis, 998-1000

asphyxiating thoracic dystrophy, 991

campomelic dysplasia, 990-991

chondroectodermal dysplasia, 994-995

diastrophic dysplasia, 995-996

ethnic factors in, 980

evaluation of, 980-983

hypophosphatasia, 987-988

in trisomies, 775

lethal, 984-994

limb defects, 996-997

molecular genetic analysis of, 983

osteogenesis imperfecta, 991-994

potentially lethal, 994-1000

short rib-polydactyly syndrome, 991

thanatophoric dysplasia, 985-987

Skin, water loss through, hyperosmolar state in, in micropremies, 135-138

Skull, anomalies of, 814, 818-820

Small-for-gestational age, 326

Small intestine, disorders of, 907-908

erythropoietin in, 531-533

herniation of, 917-918

motility of, development of, 224

Socioeconomic factors, in cerebral palsy, 287

in very low-birth weight infant outcome. *See Family factors and social support, in outcome of very low-birth weight infants.*

- Sodium, depletion of, in hyponatremia of prematurity, 142-143
restriction of, in hyperosmolar state, 137-138
- Spasticity, in cerebral palsy, functional motor outcome in, 385-387
in periventricular leukomalacia, 312
- Special education, prematurity-associated, 492-494
- Spina bifida, 793-795
- Starling's forces, disruption of, in micropremies, 134
- Stem cells, in erythropoiesis, switching from fetal to adult, 511-514
- Sternum, cleft, in pentalogy of Cantrell, 952, 958-960
- Stomach, disorders of, 905-907
motility of, development of, 224
- Strawberry-shaped skull, 818
- Streptococcal infections, group B, preterm birth in, 268
- Streptokinase, for thrombosis, 632-636
- Stress, amino acid metabolism in, 205-206
in pain, 364-365
in parents, of very low-birth weight infants, 488
- Stuck-twin syndrome. *See Twin-twin transfusion syndrome.*
- Surfactant, composition of, essential fatty acid effects on, 79-80
dysfunction of, in chronic lung disease pathogenesis, 724
in respiratory distress syndrome, cerebral palsy and, 293
- Surfactant Collaborative Neurodevelopmental Outcomes Network, disablement models of, 382
- Survival, of very low-birth weight infants, 255-262
data limitations for, 256-257
predictors of, 255-256
summary of reports for 1990s, 257-259
viability limit, 259-260
- Swallowing, development of, 223
- Temperature, environmental, versus energy expenditure, 186-187
- Teratogenesis, facial clefts in, 829
- Teratoma, intracranial, 805
- Tetralogy of Fallot, 851-854
- Thalassemia, hydrops fetalis in, 1017, 1023
- Thanatophoric dysplasia, 985-987
- Thermogenesis, diet-induced, 186
- Thiamine (vitamin B₁), metabolism and requirements of, in micropremies, 97
- Thoracentesis, in fetal hydrothorax, 889, 892
- Thoracic anomalies, 865-899. *See also Heart disease, congenital.*
- bronchopulmonary sequestration, 881-886
cystic adenomatoid malformation, 875-881, 1023-1024
diaphragmatic hernia, 866-875
embryology of, 866
hydrops fetalis in, 1017-1018, 1023-1024
hydrothorax, 886-893, 1023-1024
in skeletal anomalies. *See Skeletal anomalies.*
- Thoracoabdominal ectopia cordis (pentalogy of Cantrell), 952, 958-960
- Thoracopagus, 1043-1044
- Thrombectomy, surgical, 636
- Thrombocytopenia, 655-679
amegakaryocytic, 547, 553, 662
bone marrow failure in, 547, 553
classification of, 657-666
definition of, 655
idiopathic, 666
immune, 657-659
immune globulin in, 737-739
in genetic disorders, 661-663
in infections, 659-660
in thrombocytopenia-absent radius syndrome, 613-614, 663-664
incidence of, 655-657
mechanisms of, indicators of, 667-669
platelet transfusions in, 735-737
- Thrombocytopenia-absent radius syndrome, 613
bone marrow failure in, 547, 554-555
- Thrombolytic therapy, for thrombosis, 632-636
- Thrombophilia, thrombosis in, 627
- Thrombopoietin, therapeutic use of, in necrotizing enterocolitis, 701, 704
- Thrombosis, 623-641
arterial, presentation of, 627
diagnosis of, 628-629, 747-750
in prothrombotic disorders, 629-631
incidence of, 625
physiology of, 623-625
presentation of, 627-628, 747
risk factors for, 625-627, 748
thrombocytopenia in, 664-665
treatment of, 631-636
approach to, 751-753
heparin in, 631-632
observation in, 631
thrombectomy in, 636
thrombolytic therapy in, 632-636
- umbilical cord, 969
venous, presentation of, 627-628
- Thumb, hitchhiker, in diastrophic dysplasia, 995
- Thyroid gland, anomalies of, 834
- Thyroid hormone, abnormalities of, cerebral palsy in, 287
- Thyroxine, deficiency of, in micropremies, 126-127

- Tissue plasminogen activator, for thrombosis, 632-636
- Tocopherols, metabolism and requirements of, in micropremies, 108-110
- Tongue, anomalies of, 817, 829-830
- Tpo peptide, in thrombocytopenia, measurement of, 668
replacement of, 670-671
- Trace elements, metabolism and requirements of, in micropremies, 119-129
copper, 123-125
iodine, 126-127
iron, 119-121
manganese, 127
selenium, 125-126
zinc, 121-123
- Tracer studies. See *Radioisotope studies*.
- Trachea, occlusion of, intrauterine, in diaphragmatic hernia management, 872-873
- Tracheoesophageal fistula, 903-905
- Transfusion, erythrocyte, approach to, 734-735
granulocyte, approach to, 737
in anemia, requirements for, erythropoietin and, 683-688, 691-692
in hyperbilirubinemia, 176-178
neutrophil, approach to, 737
in neutropenia, 590-591
platelet, approach to, 735-737
in thrombocytopenia, 669
- twin-twin. See *Twin-twin transfusion syndrome*.
- Transient hypothyroxinemia of prematurity, cerebral palsy in, 287
- Transplantation, heart, in hypoplastic left heart syndrome, 845
- Transposition of great arteries, 856-858
- Treacher-Collins syndrome, 829-831
- Tricuspid valve, displacement of, in Ebstein's anomaly, 847-849
- Triglycerides, in lipid emulsions, 58-59
- Triplegia, in cerebral palsy, functional motor outcome in, 385-387
- Triplet gestations. See *Multiple gestations*.
- Triplody, ultrasonography of, major abnormalities, 772-773
- Trisomies, thrombocytopenia in, 662
ultrasonography of, early growth restriction in, 769
fetal heart rate in, 769
- Trisomy 8, ultrasonography of, major abnormalities in, 763-764
- Trisomy 13 (Patau's syndrome), ultrasonography of, 762
major abnormalities, 772
major abnormalities in, 763-764
skeletal anomalies in, 775
- Trisomy 18 (Edward's syndrome), 802-803
ultrasonography of, 762
choroid plexus cysts in, 778-780
major abnormalities in, 772
skeletal anomalies in, 775
- Trisomy 21 (Down syndrome), bone marrow failure in, 546, 551-552
thrombocytopenia in, 662
ultrasonography of, 762
amniocentesis with, 781-782
choroid plexus cysts in, 778-780
echogenic bowel in, 774-775
major abnormalities, 772
major abnormalities in, 763
mild cerebral ventricular dilatation in, 780-781
nuchal thickening in, 773-774
nuchal transparency in, 765-767, 769
papillary muscle calcification in, 776-778
renal abnormalities in, 775-776
skeletal anomalies in, 775
- Trophic feeding, for micropremies, 227-229
- Truncus arteriosus, 859-861
- Tryptophan, supplementation with, eosinophilia due to, 617
- Tube thoracostomy, 893
- Tubes, for enteral feeding, 227
- Tumor(s), hydrops fetalis in, 1018, 1024
intracranial, 805
umbilical cord, 968-969
- Tumor necrosis factor- α , in labor control, 267
- Turner's syndrome, thrombocytopenia in, 662
- Twin gestations. See also *Multiple gestations*.
cerebral palsy risk in, 287-288
conjoined, 720
- Twin reversed arterial perfusion syndrome, 1038-1042
- Twin-twin transfusion syndrome, 1033-1038
differential diagnosis of, 1035
hydrops fetalis in, 1018-1019, 1024-1025
incidence of, 1034
management of, 1036-1038
pathology of, 1033-1034
prenatal appearance of, 1034
- Ultrasonography, cervical, in preterm labor prediction, 273-275
cranial, in intraventricular hemorrhage, 305-307, 310
in periventricular leukomalacia, 305, 308, 310, 312
in ventriculomegaly, 305, 309-310, 314-315
timing of, 309-310

- versus magnetic resonance imaging, 315-316
 - in chromosomal abnormalities, **761-789**
 - central nervous system, 780-781
 - choroid plexus cysts, 778-780
 - Doppler, 769
 - early growth restriction in, 769
 - echogenic bowel, 774-775, 912-914
 - fetal heart rate in, 769
 - first trimester, 763-770
 - major, 763-764, 772-773
 - nuchal thickening, 773-774
 - nuchal translucency marker in, 764-769
 - capillary muscle calcification, 776-778
 - renal abnormalities, 775-776
 - risk assessment in, 781-782
 - second trimester, 770-782
 - skeletal anomalies, 775
 - in congenital anomalies. *See* specific anomalies.
 - three-dimensional, 834-835
 - Umbilical cord, anomalies of, 966-972
 - alpha-fetoprotein levels in, 947-948
 - body stalk anomaly, 949, 952-954
 - congenital absence, 949, 952-954
 - cysts, 967-968
 - embryology of, 947-948, 950-951, 965-966
 - funic presentation, 970-971
 - knots, 972
 - masses, 967-969
 - nuchal, 971-972
 - omphalocele. *See* *Omphalocele*.
 - persistent right vein, 967
 - prolapse, 970-971
 - short, 949, 952-954
 - single artery, 966-976
 - tumors, 968-969
 - varices, 968
 - vasa previa, 970
 - vascular anomalies, 967-969
 - velamentous insertion, 969
 - coagulation of, in twin reversed arterial perfusion syndrome, 1041-1042
 - occlusion of, in twin reversed arterial perfusion syndrome, 1041
 - Urea, metabolism of, 40-44
 - recycling of, 43-44
 - synthesis of, 41-43
 - Ureaplasma* infections, in chronic lung disease pathogenesis, 720
 - preterm birth in, 269
 - Ureter, dilatation of, 930
 - Ureteroceles, 930
 - Ureteropelvic junction obstruction, 929-930
 - Urethra, anomalies of, 931-932
 - Urethral valves, posterior, 930-931
 - Urine, granulocyte colony-stimulating factor in, 562
 - Urokinase, for thrombosis, 632-636
 - Urologic anomalies, **921-945**
 - bladder exstrophy, 925-926, 952, 962-963
 - cloaca exstrophy, 925-926, 952, 960-962
 - embryology of, 921-922
 - hydrops fetalis in, 1018, 1024
 - imaging of, 923-924
 - in chromosomal abnormalities, 939-940
 - in Meckel-Gruber syndrome, 937-939
 - in MURCS association, 939
 - in VACTERL association, 939
 - kidney, agenesis, 924-925
 - cystic disease, 933-937
 - obstruction, 927-933
 - hydronephrosis in, 775-776, 927-929
 - lower tract, 930-933
 - upper tract, 929-930
 - versus normal function, 922-923
 - Uterus, activation of, in labor, 264-265
 - activity of, monitoring of, in preterm labor prediction, 275
 - erythropoietin in, 531
 - infections of, as cerebral palsy antecedent, 289-290
 - preterm birth in, 268-270
 - interventions within, cystic adenomatoid malformation resection, 879-880
 - diaphragmatic hernia repair, 872-874
 - fetal hydrothorax drainage, 890-892
 - in fetal urinary obstruction, 932-933
- VACTERL association, 939
- Vaginosis, bacterial, preterm birth in, 270
- Vanishing twin syndrome, 1034
- Varices, umbilical cord, 968
- Vasa previa, 970
- VATER association, 904
- Velocardiofacial syndrome, 827-828
- Vena cava, thrombosis of, 628
- Venous thrombosis, 627-628
- Ventricle(s), double-inlet, 858-859
 - right, double-outlet, 854-856
 - hypoplastic, 851
- Ventricular septal defect, 849-851
- Ventriculomegaly, 305, 795-799
 - imaging of, for outcome prediction, 314-315
 - types of, 315-316
 - ultrasonography in, 305, 309-310, 314-315
 - mild, 780-781
- Very low-birth weight infants, arousal in, 373
 - attention in, 373
 - outcome of, biology versus environment, **461-481**
 - brain development. *See* *Brain, development of*.

- Very low-birth weight infants (*Continued*)
 cerebral palsy antecedents, 285-302
 economics and, 483-497
 family factors in, 433-459
 functional, 381-401
 growth. *See Growth.*
 in adolescence, 372-372, 407-416, 421-432
 in multiple gestations, 325-345
 pain perception and, 363-379
 preterm birth pathogenesis and markers, 263-283
 quality of life, 403-419
 respiratory, 428-431, 446-447
 survival rates, 255-262
 self-regulation in, 373
 Viability, limit of, in neonates, 259-260
 Vineland Adaptive Behavior Scale, in very low-birth weight infant evaluation, 391, 394
 Vision, development of, essential fatty acids for, 85
 limitations of, in very low-birth weight infant survivors, family and social factors affecting, 446-447
 Vitamin(s), metabolism and requirements of, in micropremies, 95-118
 fat-soluble, 104-112
 water-soluble, 96-104
 Vitamin A, metabolism and requirements of, in micropremies, 104-106
 Vitamin B₁, metabolism and requirements of, in micropremies, 97
 Vitamin B₂, metabolism and requirements of, in micropremies, 100-101
 Vitamin B₆, metabolism and requirements of, in micropremies, 101
 Vitamin B₁₂, metabolism and requirements of, in micropremies, 101-102
 Vitamin C, metabolism and requirements of, in micropremies, 96-97
 Vitamin D, metabolism and requirements of, in micropremies, 106-108, 154-155
 Vitamin E, metabolism and requirements of, in micropremies, 108-110
 Vitamin K, metabolism and requirements of, in micropremies, 110-112
 Vitelline artery, persistent, 969
 Water, doubly labeled, in energy expenditure measurement, 184-185
 transepidermal loss of, hyperosmolar state in, in micropremies, 135-138
 Weight. *See also Birth weight.*
 of very low-birth weight infant survivors, in adolescence, 421-428
 White matter damage. *See also Periventricular leukomalacia.*
 antecedents of. *See Cerebral palsy, antecedents of.*
 Wiskott-Aldrich syndrome, thrombocytopenia in, 662-663
 WT syndrome, bone marrow failure in, 547
 Xiphopagus, 1043-1044
 Yolk sac, erythropoiesis in, 509
 Zinc, metabolism and requirements of, in micropremies, 121-123
 Zygosity, of multiple gestations, outcome and, 354

